title: Hypertension and Diabetic Nephropathy.
abstract: Diabetic nephropathy (DN) is a major complication of both type 1 and type 2 diabetes. DN is the most common cause of end-stage renal disease, and it markedly enhances the risk of cardiovascular events. An elevated urinary albumin excretion rate, increased blood pressure (BP), and a continual loss of renal function are characteristics of DN. Screening for microalbuminuria is central to diabetes care, and antihypertensive agents are used for the primary prevention and treatment of DN. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers play central roles and have protective properties beyond their BP-lowering effects. BP control in relation to DN is the main focus of this review, but tight control of the glucose level is equally important. There is an unmet need for new treatment options, and while a few promising candidates exist, their roles in clinical practice have not yet been determined.
authors.forename: Jeppe
authors.initials: J
authors.lastname: Skov
authors.forename: Jens Sandahl
authors.initials: JS
authors.lastname: Christiansen
authors.forename: Per Løgstrup
authors.initials: PL
authors.lastname: Poulsen
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D003928:Diabetic Nephropathies / Q000150:complications* / Q000628:therapy; D006801:Humans; D006977:Hypertension, Renal / Q000209:etiology* / Q000628:therapy
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose